Skip to main content
Log in

FGFR-Inhibition beim cholangiozellulären Karzinom

FGFR inhibition in cholangiocarcinoma

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S (2015) Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget 6:14744–14753

    Article  PubMed  PubMed Central  Google Scholar 

  2. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS ONE 9:e115383

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hakan Alakus.

Ethics declarations

Interessenkonflikt

H. Alakus und C. Bruns geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alakus, H., Bruns, C. FGFR-Inhibition beim cholangiozellulären Karzinom. Onkologe 24, 425–426 (2018). https://doi.org/10.1007/s00761-018-0370-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-018-0370-7

Navigation